# Cognitive Protective Effect of Newer Antidiabetic Drugs

> **NCT05347459** · — · UNKNOWN · sponsor: **Alexandria University** · enrollment: 100 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Empagliflozin
- **DRUG:** Canagliflozin
- **DRUG:** Sitagliptin
- **DRUG:** Saxagliptin
- **DRUG:** Linagliptin
- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT05347459
- **Lead sponsor:** Alexandria University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-02
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05347459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05347459, "Cognitive Protective Effect of Newer Antidiabetic Drugs". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05347459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*